Effect of CytoSorb Adsorber on Hemodynamic and Immunological Parameters in Critical Ill Patients With COVID-19

Effect of CytoSorb Adsorber on Hemodynamic and Immunological Parameters in Critical Ill Patients With COVID-19

This prospective randomized single Center study investigates to what extent the physical elimination of the inflammatory mediators using the CytoSorb adsorber reduces the morbidity of severely and critically ill patients with Covid-19.

Inclusion Criteria:

• confirmed COVID-19 disease
• refractory shock with need for norepinephrine ≥ 0.2 μg/kg/min for MAP ≥ 65 mmHg
• IL6 ≥ 500 ng/l
• Indication for CRRT or ECMO

Exclusion Criteria:

• Liver cirrhosis Child Pugh C
• "do not resuscitate"-order
• expected survival due to comorbidities < 14 days
• pregnancy or breastfeeding
• participation in another interventional trial